No quarterly revenue total was found in Oruka Therapeutics, Inc.'s SEC filings.
Oruka Therapeutics, Inc. (ORKA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$33.1 million. As of Jun 30, 2026 it held $1.1 billion in cash and investments and $2.5 million in total debt.
Revenue
—
Net income
$-41.21M
-67.7% vs year-ago quarter
Operating cash flow
$-33.15M
-43.2% vs year-ago quarter
Free cash flow
$-33.15M
-43.0% vs year-ago quarter
EPS
$-0.46
-15.0% vs prior quarter
Dividend per share
None
Shares outstanding
66.21M
+76.8% vs year-ago quarter
Net cash
$1.12B
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ORKA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Menlo Park, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 907654
- Former names
- ARCA biopharma, Inc. (until Aug 30, 2024); NUVELO INC (until Jan 27, 2009); HYSEQ INC (until Jan 28, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$50.1M | -$36.4M | -$34.4M | -$34.1M | -$28.4M |
| Net income | -$41.2M | -$31.8M | -$29.6M | -$30.3M | -$24.6M |
| Diluted EPS | — | — | — | — | -$0.46 |
| Operating cash flow | -$33.1M | -$23.6M | -$22.6M | -$21.6M | -$23.1M |
| Free cash flow | -$33.1M | -$23.7M | -$22.7M | -$21.7M | -$23.2M |
| Total assets | $1.1B | $504.5M | $488.6M | $509.3M | $357.4M |
| Total liabilities | $24.8M | $17.8M | $16.7M | $22.5M | $13.8M |
| Stockholders' equity | $1.1B | $486.7M | $471.9M | $486.8M | $343.6M |
| Cash and investments | $1.1B | $496.0M | $479.6M | $500.9M | $351.5M |
| Total debt | $2.5M | $1.8M | $1.9M | $1.9M | $2.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 24, 2026 | Aug 24, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 2, 2026 |
| 8-K |
Current report
Other events
|
Jun 1, 2026 | May 29, 2026 |
All 1001 Oruka Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.